Volume 13, Issue 1 (volume 13, number 1 2021)                   IJDO 2021, 13(1): 10-18 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Taheri H, Rafaiee R, Rafaiee R. Prevalence of Complications of Diabetes and Risk Factors Among Patients with Diabetes in the Diabetes Clinic in Southeast of Iran. IJDO. 2021; 13 (1) :10-18
URL: http://ijdo.ssu.ac.ir/article-1-606-en.html
Ph.D., Department of Neuroscience, School of Advanced Technologies in Medicine, Mazandaran University of Medical Sciences, Sari, Iran
Abstract:   (124 Views)
Objective: Academic health services play an important role in the prevention and control of diabetes mellitus (DM) in Iran. This study aimed at determining the prevalence of DM-related complications and the associated risk factors among patients with DM in a university-affiliated outpatient diabetes clinic of a referral hospital in Southeast of Iran, Zahedan.
Materials and Methods: This cross-sectional study was conducted from January to April 2019 in an academic diabetes clinic. A total of 334 patients with DM, whose characteristics (age, sex, family history of DM, and substance abuse), as well as laboratory and clinical information, were recorded in the baseline forms, were included. The relationship between variables were assessed by Pearson’s correlation coefficient at P-value< 0.05 and using SPSS version 20.0.
Results: The mean age of the participants was 54.27 (±11.57) years. In these patients, DM type 2 was estimated at 99.1%, and the mean duration of the disease was 8.98 (±6.93) years. The findings showed that 77.2% of the patients had poor glycemic control. Also, 85.4% of the patients had fasting blood sugar (FBS) level >126 mg/dL. There was a significant relationship between insulin-dependent therapy and drug abuse (P-value <0.001). The prevalence of hyperlipidemia (68.9%), hypertension (50.6%), retinopathy (29.6%), nephropathy (11.7%), and neuropathy (12.3%) was also determined.
Conclusion: The majority of the patients (77.2%) in this study had poor glycemic control, and 69.9% of them suffered from microvascular complications, macrovascular complications, or both. Therefore, frequent visits accompanied by patient education could help to better diabetes control
Full-Text [PDF 194 kb]   (55 Downloads)    
Type of Study: Research | Subject: Special
Received: 2021/03/13 | Accepted: 2021/03/20 | Published: 2021/03/20

1. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas. Diabetes research and clinical practice. 2019;157:107843. [DOI:10.1016/j.diabres.2019.107843]
2. Haghdoost AA, Rezazadeh Kermani M, Sadghirad B, Baradaran HR. Prevalence of type 2 diabetes in the Islamic Republic of Iran: systematic review and meta-analysis. EMHJ-Eastern Mediterranean Health Journal, 2009;15(3):591-599. [DOI:10.26719/2009.15.3.591]
3. Javanbakht M, Mashayekhi A, Baradaran HR, Haghdoost A, Afshin A. Projection of diabetes population size and associated economic burden through 2030 in Iran: evidence from micro-simulation Markov model and Bayesian meta-analysis. PloS one. 2015;10(7):e0132505. [DOI:10.1371/journal.pone.0132505]
4. Care D. 6. Glycemic targets: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Supplement 1):S61-70. [DOI:10.2337/dc19-S006]
5. Zimmerman RS. Diabetes mellitus: management of microvascular and macrovascular complications. J Cleveland Clinic: Centers for Continuing Education. 2016.
6. Khavjou OA, Saydah SH, Zhang P, Poehler DC, Neuwahl SJ, Leib AR, et al. Estimating State-Level Health Burden of Diabetes: Diabetes-Attributable Fractions for Diabetes Complications. American journal of preventive medicine. 2019;56(2):232-40. [DOI:10.1016/j.amepre.2018.09.023]
7. Rasolabadi M, Khaledi S, Ardalan M, Kalhor MM, Penjvini S, Gharib A. Diabetes research in Iran: a scientometric analysis of publications output. Acta Informatica Medica. 2015 ;23(3):160-164. [DOI:10.5455/aim.2015.23.160-164]
8. Mathew TK, Tadi P. Blood Glucose Monitoring. StatPearls [Internet]. 2020.
9. Harrabi I, Al Harbi F, Al Ghamdi S. Predictors of glycemic control among patients with type 2 diabetes in Najran Armed Forces Hospital: a pilot study. Journal of Diabetes Mellitus. 2014;4(02):141. [DOI:10.4236/jdm.2014.42021]
10. Camara A, Baldé NM, Sobngwi-Tambekou J, Kengne AP, Diallo MM, Tchatchoua AP, et al. Poor glycemic control in type 2 diabetes in the South of the Sahara: the issue of limited access to an HbA1c test. Diabetes research and clinical practice. 2015;108(1):187-92. [DOI:10.1016/j.diabres.2014.08.025]
11. Gopinath B, Prasad SM, Jayarama N, Prabhakara K. Study of factors associated with poor glycemic control in Type-2 Diabetic patients. Global journal of Medicine and public health. 2013;2(2):1-5.
12. Abougalambou S, Suleiman A, Abougalambou A. Glycaeted haemoglobin control among type 2 diabetes patients attending a teaching hospital in Malaysia. Saudi Journal of Medical Pharmaceutical Science. 2015;15:93-102.
13. Pablo CR, Mohammadnezhad M, Wilson D, Khan S. Socio-demographic Determinants of Poor Glycaemic Control among Type 2 Diabetes Mellitus (T2DM) Patients Attending Clinics at the Three Selected Health Facilities in Suva, Fiji in 2011-2016. Journal of Diabetic Complications & Medicine. 2018;3(1).
14. Adeniyi OV, Yogeswaran P, Longo-Mbenza B, Ter Goon D, Ajayi AI. Cross-sectional study of patients with type 2 diabetes in OR Tambo district, South Africa. BMJ open. 2016;6(7):e010875. [DOI:10.1136/bmjopen-2015-010875]
15. Saghir SA, Alhariri AE, Alkubati SA, Almiamn AA, Aladaileh SH, Alyousefi NA. Factors associated with poor glycemic control among type-2 diabetes mellitus patients in Yemen. Tropical Journal of Pharmaceutical Research. 2019;18(7).
16. de Pablos‐Velasco P, Parhofer KG, Bradley C, Eschwege E, Gönder-Frederick L, Maheux P, et al. Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study. Clinical endocrinology. 2014;80(1):47-56. [DOI:10.1111/cen.12119]
17. Kellow NJ, Savige GS, Khalil H. Predictors of poor glycaemic control during the initial five years post‐diagnosis in rural adults with type 2 diabetes. Australian Journal of Rural Health. 2011;19(5):267-74. [DOI:10.1111/j.1440-1584.2011.01222.x]
18. Jyun-You L, Chia-Fen M, Chao-Yu H. Medical appointment no-shows associated with poor glycaemic control among Taiwanese aborigines. Australian Journal of Rural Health. 2012;20(6):312-7. [DOI:10.1111/j.1440-1584.2012.01310.x]
19. Hasan C, Parial R, Islam M, Ahmad MNU, Kasru A. Association of HbA1c, Creatinine and Lipid Profile in Patients with Diabetic Foot Ulcer. Middle-East Journal of Scientific Research. 2013 01/01;16:1508-11.
20. Christman AL, Selvin E, Margolis DJ, Lazarus GS, Garza LA. Hemoglobin A1c predicts healing rate in diabetic wounds. Journal of Investigative Dermatology. 2011;131(10):2121-7. [DOI:10.1038/jid.2011.176]
21. Zubair M, Malik A, Ahmad J. Glycosylated hemoglobin in diabetic foot and its correlation with clinical variables in a north Indian tertiary care hospital. Journal of Diabetes and Metabolism. 2015;6(7). [DOI:10.4172/2155-6156.1000571]
22. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nature Reviews Endocrinology. 2009;5(3):150-9. [DOI:10.1038/ncpendmet1066]
23. Hirano T. Pathophysiology of diabetic dyslipidemia. Journal of atherosclerosis and thrombosis. 2018;25(9):771-82. [DOI:10.5551/jat.RV17023]
24. Dixit AK, Dey R, Suresh A, Chaudhuri S, Panda AK, Mitra A, et al. The prevalence of dyslipidemia in patients with diabetes mellitus of ayurveda Hospital. Journal of Diabetes & Metabolic Disorders. 2014;13(1):1-6. [DOI:10.1186/2251-6581-13-58]
25. Esteghamati A, Larijani B, Aghajani MH, Ghaemi F, Kermanchi J, Shahrami A, et al. Diabetes in Iran: prospective analysis from first nationwide diabetes report of National Program for Prevention and Control of Diabetes (NPPCD-2016). Scientific reports. 2017;7(1):1-0. [DOI:10.1038/s41598-017-13379-z]
26. Ozder A. Lipid profile abnormalities seen in T2DM patients in primary healthcare in Turkey: a cross-sectional study. Lipids in health and disease. 2014;13(1):1-6. [DOI:10.1186/1476-511X-13-183]
27. Dabla PK. Renal function in diabetic nephropathy. World journal of diabetes. 2010;1(2):48-56. [DOI:10.4239/wjd.v1.i2.48]
28. Perkovic V, Jardine M, Vijapurkar U, Meininger G. Renal effects of canagliflozin in type 2 diabetes mellitus. Current medical research and opinion. 2015;31(12):2219-31. [DOI:10.1185/03007995.2015.1092128]
29. Al Nozha OM. Diabetes care and control: the effect of frequent visits to diabetes care center. Annals of Saudi medicine. 2014;34(3):229-34. [DOI:10.5144/0256-4947.2014.229]

Add your comments about this article : Your username or Email:

© 2021 All Rights Reserved | Iranian Journal of Diabetes and Obesity

Designed & Developed by : Yektaweb